287 related articles for article (PubMed ID: 8381275)
1. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent.
Masuoka H; Ito M; Sugioka M; Kozeki H; Konishi T; Tanaka T; Nakano T
Biochem Biophys Res Commun; 1993 Jan; 190(2):412-7. PubMed ID: 8381275
[TBL] [Abstract][Full Text] [Related]
2. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
4. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
Torphy TJ; Zhou HL; Burman M; Huang LB
Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
[TBL] [Abstract][Full Text] [Related]
5. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
Torphy TJ; Cieslinski LB
Mol Pharmacol; 1990 Feb; 37(2):206-14. PubMed ID: 2154670
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
[TBL] [Abstract][Full Text] [Related]
7. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.
Harrison SA; Reifsnyder DH; Gallis B; Cadd GG; Beavo JA
Mol Pharmacol; 1986 May; 29(5):506-14. PubMed ID: 3010079
[TBL] [Abstract][Full Text] [Related]
9. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Beierwaltes WH
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
[TBL] [Abstract][Full Text] [Related]
10. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
[TBL] [Abstract][Full Text] [Related]
11. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine.
Podzuweit T; Nennstiel P; Müller A
Cell Signal; 1995 Sep; 7(7):733-8. PubMed ID: 8519602
[TBL] [Abstract][Full Text] [Related]
12. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions.
Lugnier C; Muller B; Le Bec A; Beaudry C; Rousseau E
J Pharmacol Exp Ther; 1993 Jun; 265(3):1142-51. PubMed ID: 8389853
[TBL] [Abstract][Full Text] [Related]
13. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
15. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
16. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.
Weishaar RE; Burrows SD; Kobylarz DC; Quade MM; Evans DB
Biochem Pharmacol; 1986 Mar; 35(5):787-800. PubMed ID: 3006691
[TBL] [Abstract][Full Text] [Related]
17. Changes in phosphodiesterase activity in the developing rat submandibular gland.
Tanaka S; Shimooka S; Shimomura H
Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes.
Sugioka M; Ito M; Masuoka H; Ichikawa K; Konishi T; Tanaka T; Nakano T
Naunyn Schmiedebergs Arch Pharmacol; 1994 Sep; 350(3):284-93. PubMed ID: 7824045
[TBL] [Abstract][Full Text] [Related]
19. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
Maurice DH
Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
